TY - JOUR
T1 - The prognostic importance of worsening renal function during an acute myocardial infarction on long-term mortality
AU - Amin, Amit P.
AU - Spertus, John A.
AU - Reid, Kimberly J.
AU - Lan, Xiao
AU - Buchanan, Donna M.
AU - Decker, Carole
AU - Masoudi, Frederick A.
N1 - Funding Information:
Funding sources: The Prospective Registry Evaluating Myocardial Infarction: Events And Recovery (PREMIER) registry study was funded in part by Cardiovascular Therapeutics , 3172 Porter Dr, Palo Alto, CA 94304 and Cardiovascular Outcomes Inc. Drs. Amin and Spertus were funded, in part, by an award from the American Heart Association Pharmaceutical Round Table and David and Stevie Spina.
PY - 2010/12
Y1 - 2010/12
N2 - Background: Although an acute worsening in renal function (WRF) commonly occurs among patients hospitalized for acute myocardial infarction (AMI), its long-term prognostic significance is unknown. We examined predictors of WRF and its association with 4-year mortality. Methods: Acute myocardial infarction patients from the multicenter PREMIER study (N = 2,098) who survived to hospital discharge were followed for at least 4 years. Worsening in renal function was defined as an increase in creatinine during hospitalization of ≥0.3 mg/dL above the admission value. Correlates of WRF were determined with multivariable logistic regression models and used, along with other important clinical covariates, in Cox proportional hazards models to define the independent association between WRF and mortality. Results: Worsening in renal function was observed in 393 (18.7%) of AMI survivors. Diabetes, left ventricular systolic dysfunction, and a history of chronic kidney disease (documented history of renal failure with baseline creatinine >2.5 mg/dL) were independently associated with WRF. During 4-year follow-up, 386 (18.6%) patients died. Mortality was significantly higher in the WRF group (36.6% vs 14.4% in those without WRF, P < .001). After adjusting for other factors associated with WRF and long-term mortality, including baseline creatinine, WRF was independently associated with a higher risk of death (hazard ratio = 1.64, 95% CI 1.23-2.19). Conclusions: Worsening in renal function occurs in approximately 1 of 6 AMI survivors and is independently associated with an adverse long-term prognosis. Further studies on interventions to minimize WRF or to more aggressively treat patients developing WRF should be tested.
AB - Background: Although an acute worsening in renal function (WRF) commonly occurs among patients hospitalized for acute myocardial infarction (AMI), its long-term prognostic significance is unknown. We examined predictors of WRF and its association with 4-year mortality. Methods: Acute myocardial infarction patients from the multicenter PREMIER study (N = 2,098) who survived to hospital discharge were followed for at least 4 years. Worsening in renal function was defined as an increase in creatinine during hospitalization of ≥0.3 mg/dL above the admission value. Correlates of WRF were determined with multivariable logistic regression models and used, along with other important clinical covariates, in Cox proportional hazards models to define the independent association between WRF and mortality. Results: Worsening in renal function was observed in 393 (18.7%) of AMI survivors. Diabetes, left ventricular systolic dysfunction, and a history of chronic kidney disease (documented history of renal failure with baseline creatinine >2.5 mg/dL) were independently associated with WRF. During 4-year follow-up, 386 (18.6%) patients died. Mortality was significantly higher in the WRF group (36.6% vs 14.4% in those without WRF, P < .001). After adjusting for other factors associated with WRF and long-term mortality, including baseline creatinine, WRF was independently associated with a higher risk of death (hazard ratio = 1.64, 95% CI 1.23-2.19). Conclusions: Worsening in renal function occurs in approximately 1 of 6 AMI survivors and is independently associated with an adverse long-term prognosis. Further studies on interventions to minimize WRF or to more aggressively treat patients developing WRF should be tested.
UR - https://www.scopus.com/pages/publications/78650117277
U2 - 10.1016/j.ahj.2010.08.007
DO - 10.1016/j.ahj.2010.08.007
M3 - Article
C2 - 21146659
AN - SCOPUS:78650117277
SN - 0002-8703
VL - 160
SP - 1065
EP - 1071
JO - American heart journal
JF - American heart journal
IS - 6
ER -